Therefore, we speculated that CLDN6 may affect c–MYC by interacting with TAZ, and the mechanism by which CLDN6/TAZ/c–MYC mediated signaling controls glycolysis and proliferation in breast cancer has not been investigated to our knowledge. Here, CLDN6 is linked to breast carcinoma.